Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021

Molecular Insights into Pediatric Brain Tumors Have the Potential to Transform Therapy

(2014) A. Gajjar et al.   CLINICAL CANCER RESEARCH

Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas

(2014) Andrew D. Norden et al.   JOURNAL OF NEURO-ONCOLOGY

Dose-dependent response of tumor vasculature to radiation therapy in combination with Sunitinib depicted by three-dimensional high-frequency power Doppler ultrasound

(2013) Ahmed El Kaffas et al.   ANGIOGENESIS

Phase II study of cilengitide in the treatment of refractory or relapsed high-grade gliomas in children: A report from the Children's Oncology Group

(2013) T. J. MacDonald et al.   NEURO-ONCOLOGY

A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma

(2012) Edward Pan et al.   JOURNAL OF NEURO-ONCOLOGY

A phase I/II trial of vandetanib for patients with recurrent malignant glioma

(2012) T. N. Kreisl et al.   NEURO-ONCOLOGY

The addition of Sunitinib to radiation delays tumor growth in a murine model of glioblastoma

(2012) Randy D’Amico et al.   NEUROLOGICAL RESEARCH

A phase 1b trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies

(2011) Evan J. Wuthrick et al.   CANCER

Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children’s Oncology Group study

(2011) Steven G. DuBois et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase I and Pharmacokinetic Study of Sunitinib in Pediatric Patients with Refractory Solid Tumors: A Children's Oncology Group Study

(2011) S. G. DuBois et al.   CLINICAL CANCER RESEARCH

Integrated Molecular Genetic Profiling of Pediatric High-Grade Gliomas Reveals Key Differences With the Adult Disease

(2010) Barbara S. Paugh et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II study of sunitinib malate in patients with recurrent high-grade glioma

(2010) B. Neyns et al.   JOURNAL OF NEURO-ONCOLOGY

Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02)

(2010) F. M. Iwamoto et al.   NEURO-ONCOLOGY

Expression of KIT Receptor Tyrosine Kinase in Endothelial Cells of Juvenile Brain Tumors

(2009) Marjut Puputti et al.   BRAIN PATHOLOGY

Response to Sunitinib Malate in Advanced Alveolar Soft Part Sarcoma

(2009) S. Stacchiotti et al.   CLINICAL CANCER RESEARCH

A Population Pharmacokinetic Meta-analysis of Sunitinib Malate (SU11248) and Its Primary Metabolite (SU12662) in Healthy Volunteers and Oncology Patients

(2009) B. E. Houk et al.   CLINICAL CANCER RESEARCH

Molecular Target Modulation, Imaging, and Clinical Evaluation of Gastrointestinal Stromal Tumor Patients Treated with Sunitinib Malate after Imatinib Failure

(2009) G. D. Demetri et al.   CLINICAL CANCER RESEARCH

Efficacy of Sunitinib and Radiotherapy in Genetically Engineered Mouse Model of Soft-Tissue Sarcoma

(2009) Sam S. Yoon et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma

(2008) Manuela Schmidinger et al.   JOURNAL OF CLINICAL ONCOLOGY